Rapport’s RAP-219 Phase 2a Success Drives 188.86% YTD Stock Surge
By ATTN Desk · Editorial oversight: Sean Han
Introduction to Rapport Therapeutics Inc.
Rapport Therapeutics Inc. (NASDAQ: RAPP; Korean: 라포 테라퓨틱스) is a privately held biotechnology company founded in 2022 and headquartered in Boston, Massachusetts, with an additional office in San Diego, California. The firm develops precision neuroscience therapies by targeting receptor-associated proteins (RAPs) to modulate neuronal circuits implicated in central nervous system (CNS) disorders.
| Ticker | Exchange | Price (USD) | YTD Change | Volume | Date |
|---|---|---|---|---|---|
| RAPP | NASDAQ | 41.48 | +188.86% | 1,720,073 | 2025-09-08 |
Corporate Structure and Experience
With 11–50 employees, Rapport was launched through a partnership between Third Rock Ventures and Johnson & Johnson Innovation – JJDC. The leadership team possesses extensive experience across neuroscience discovery, clinical development, commercialization, and finance. Chief Executive Officer Abe Ceesay has nearly 20 years of biopharma experience, including roles at Cerevel Therapeutics and Tiburio Therapeutics. Chief Scientific Officer David … previously led neuroscience discovery at Janssen and Eli Lilly. Chief Financial Officer Troy … has facilitated over $4 billion in life science capital and was involved in multiple IPOs and follow-on offerings. The broader management team includes expertise in marketing, operations, and clinical strategy.
Neuroscience Therapies by Milad Fakurian
Recent Developments and News
On September 8, 2025, Rapport announced topline results from its Phase 2a study of RAP-219 in patients with drug-resistant focal onset seizures. The data indicated statistically significant reductions in prolonged seizure episodes, with a safety profile consistent with previous studies. A Current Report on Form 8-K filed the same day outlines plans to initiate registrational trials.
On August 7, 2025, the company filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025, detailing operational updates and pipeline progress. A concurrent Form 8-K (items 2.02, 7.01, 9.01) addressed organizational and regulatory matters, including updates to corporate policies and disclosures.
Financial and Strategic Analysis
As of September 8, 2025, Rapport’s share price stood at $41.48, reflecting a year-to-date gain of 188.86% with daily trading volume of 1.72 million shares. The company funds its research and development through a combination of private financing and capital markets transactions, drawing on the CFO’s experience in life science fundraising. Strategically, Rapport’s lead asset, RAP-219—a TARPγ8-targeted AMPAR modulator—targets focal epilepsy with neuroanatomical specificity. Additional programs include discovery-stage modulators of α6 and α9α10 nicotinic acetylcholine receptors for chronic pain and hearing disorders, respectively. This focused pipeline aims to deliver differentiated clinical profiles compared with non-selective CNS agents.
Market Position and Industry Context
The global CNS therapeutics market encompasses epilepsy, pain, bipolar disorder, and sensory disorders, with combined annual revenues exceeding $20 billion. Traditional glutamate-blocking drugs can result in side effects such as sedation and cognitive impairment; Rapport’s RAP-219 aims to minimize these effects by selectively targeting TARPγ8, which is concentrated in hippocampal and cortical regions involved in focal seizures. Competitors include neurology divisions of large pharmaceutical companies and smaller biotech firms developing novel small molecules or biologics. Key industry challenges include high clinical development costs, strict regulatory requirements, and competition for patient enrollment in CNS trials. Rapport’s precision medicine approach positions it to address niche indications with unmet clinical demands.
tl;dr
On September 8, 2025, Rapport Therapeutics reported Phase 2a data for RAP-219 in drug-resistant focal onset seizures and filed an 8-K announcing plans to advance into registrational trials. The stock trades at $41.48 (up 188.86% YTD). The focus is on initiation timelines for pivotal studies, forthcoming data readouts, and financing to support late-stage development.